secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-045729
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports FY2024 net loss $13.7M; cash $18.7M, funding into mid-2026
------------------------------------------------------------------------------

- Net loss $13.7M in 2024 (vs $34.4M in 2023); R&D $14.5M, G&A $9.7M.
- Cash $18.7M at Dec 31, 2024; plus $9.7M net from March 2025 debt facility; runway into mid-2026.
- Phase 2 KOURAGE trial in AKI enrolling; data expected around end of 2025.
- Post-hoc CARDEA analysis: 62.7% relative mortality reduction in AKI patients at day 30.
- End-of-Phase 2 FDA meeting for acute pancreatitis program planned for mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/0000950170-25-045729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017025045729/ck0001534133-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer